The global market for viral vector contract development and manufacturing organizations is anticipated to register significant growth over the forecast period. Leading market players have introduced new programmes and technologies to improve viral vector production in response to the rising demand of viral vectors for gene therapy. Additionally, the government is increasing its investments in the creation of innovative technologies and manufacturing facilities, which is fueling market expansion.
The COVID-19 pandemic created a significant commercial opportunity for the production of viral vectors. Additionally, market participants are refocusing their corporate attention on the creation of viral vectors for the SARS-CoV-2 vaccine. Viral vectors are frequently used as research and development tools for SARS-CoV-2 vaccines. As viral vector-based vaccines may be produced and created reasonably fast with the use of the same building blocks, the ongoing COVID-19 pandemic has prompted investment in this area in quest of a vaccine.
Based on vector type, the adeno-associated virus (AAV) segment is anticipated to register fastest CAGR during the forecast period. The growing use of AAV in vaccines and the increasing use of corporate growth strategies like expansion, mergers and acquisitions, and product launches are factors contributing to the segmental growth. For instance, in November 2022, Thermo Fisher Scientific, Inc. launched the Gibco CTS AAV-MAX Helper-Free AAV Production System, a brand-new all-in-one tool developed to meet clinical and commercial needs for the economical & scalable development of AAV-based gene treatments.
The North America region is expected to dominate the market over the forecast period. This is due to the significant number of centres and institutes that are involved in the research and development of new therapies, which are the main factors that have contributed to the high share of this regional market. Also, federal agencies have made investments to strengthen the local cell therapy research infrastructure.
The key market players include Thermo Fischer Scientific, Inc., Oxford Biomedica, Charles River Laboratories International, Inc., Creative Biogene, GenScript ProBio, Merck KGaA, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Lonza, Curia Global, Inc., and Takara Bio Inc. They are using a variety of stratergies, including merger & acquisition, partnership and expansion. For instance, in August 2022, Thermo Fischer Scientific, Inc. announced opening of a new viral vector manufacturing facility in Plainville, Massachusetts.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.